Subcutaneous. Learn more.

30 mg injected subcutaneously in the abdominal area. If response is inadequate or symptoms recur, additional injections of 30 mg may be administered at intervals of at least 6 hours. . Learn more.

Learn more.

30 mg SC (subcutaneous) in abdomen. If inadequate response or recurring symptoms, administer additional 30 mg injections at ≥6-hour intervals.. Learn more.

®()	Sajazir®(Icatibant)

Prescription Only	Prescription Only SAJAZIR (icatibant) injection is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and...
Dosage & Administration	Dosage & Administration comparison data
Administration
Learn more.	Subcutaneous. Learn more.
Dosing
Learn more.	30 mg injected subcutaneously in the abdominal area. If response is inadequate or symptoms recur, additional injections of 30 mg may be administered at intervals of at least 6 hours. . Learn more.
Latin Shorthand
Learn more.	30 mg SC (subcutaneous) in abdomen. If inadequate response or recurring symptoms, administer additional 30 mg injections at ≥6-hour intervals.. Learn more.
Financial Assistance	Financial Assistance comparison data
Out-Of-Pocket Costs With Copay Card
Learn more.	Learn more.
Annual Cap
Learn more.	Learn more.
Assistance Expiration
Learn more.	Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Physician Advisory	Physician Advisory comparison data
Adverse Reactions
Learn more.	The most commonly reported adverse reactions were injection site reactions, which occurred in almost all patients (97%) in clinical trials. Other common adverse reactions occurring in greater than 1% of patients included pyrexia, transaminase increase, dizziness, and rash. . Learn more.
Mechanism of Actions (MoA)
Learn more.	Drugs used in Hereditary Angioedema. Learn more.
Special Populations

® Alternatives